XML 50 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 8 - Income Taxes
9 Months Ended
Jun. 30, 2014
Notes  
Note 8 - Income Taxes

Note 8 – Income Taxes

 

The Company’s subsidiaries are governed by the Income Tax Law of the People’s Republic of China.  Their income is taxed at the 25% statutory rate. Hedi Medicine has been taxed at a flat rate of 260 RMB per quarter since calendar 2012.

 

The following table reconciles the U.S. statutory rates to the Company’s effective tax rate for the nine months ended June 30, 2014 and 2013:

 

 

 

Nine month Ended June 30

 

 

 

2014

2013

 

US statutory income tax rate

 

 

35

%

 

 

35%

Non-taxable item in US

 

 

0

%

 

 

0%

Change in valuation allowance - US

 

 

-35

%

 

 

-35%

China income tax statutory statutory rate

 

 

25

%

 

 

25%

Change in valuation allowance - China

 

 

-25

%

 

 

-25%

Effective rate

 

 

-

 

 

 

-

 

 

As of June 30, 2014, net operating loss carry forwards for United States and China income tax purposes amounted to $5.1 million and $8 million, which may be available to reduce future years' taxable income. These carry forwards will expire, if not utilized, beginning in 2028 through 2033 for U.S tax purpose and 2017 to 2018 for China income tax purposes. Management believes that the realization of the benefits arising from the losses recognized in the US is uncertain due to the Company's business operations being primarily conducted in China and foreign income not being recognized in the United States for federal income tax purposes. It is also uncertain that the China business operations will generate taxable income in the future. Accordingly, the Company has provided a 100% valuation allowance as of the balance sheet dates, for the temporary differences related to the loss carry-forwards.

$5,100,000

$8,000,000

 

The following table reconciles the changes in deferred tax asset for the nine months ended June 30, 2014 and 2013:

 

 

 

June 30,

2014

June 30,

2013

United States:

 

 

 

 

 

 

Deferred tax asset-beginning

 

$

855,293

 

 

$

658,622

Addition: loss carry-forward

 

 

13,052

 

 

 

195,315

Valuation allowance-beginning

 

 

(855,293

)

 

 

(658,622)

Addition: valuation allowance

 

 

(13,052

)

 

 

(195,315)

Deferred tax asset net

 

$

-

 

$

     -

 

The Company’s open tax years for its federal and state income tax returns are for the tax years after 2010. These tax returns are subject to examination by the tax authorities.